When Innovation and Commercialization Collide: A Patient Advocate View in Neuroblastoma

MeSH terms

• Age Factors
• Antineoplastic Agents, Immunological / economics
• Antineoplastic Agents, Immunological / therapeutic use*
• Commerce* / economics
• Cost-Benefit Analysis
• Diffusion of Innovation
• Drug Approval
• Drug Costs
• Drug Development* / economics
• Gangliosides / antagonists & inhibitors
• Gangliosides / immunology
• Humans
• Immunotherapy* / economics
• Neuroblastoma / drug therapy*
• Neuroblastoma / economics
• Neuroblastoma / immunology
• Neuroblastoma / pathology
• Patient Advocacy* / economics
• Rare Diseases / drug therapy*
• Rare Diseases / economics
• Rare Diseases / immunology
• Rare Diseases / pathology
• Therapies, Investigational* / economics
• Treatment Outcome